The above findings were corroborated by analysis of AML cell lines (MOLM-13, MOLM-14, and ME1), which also showed increased sensitivity to CPX-351 and increased drug uptake in the presence of FLT3-ITD or FLT3-activating mutations, compared with other genetic abnormalities (12). The gene discussed is FLT3; the disease is acute myeloid leukemia.